Molecular residual disease, or MRD, testing is emerging as a powerful tool in breast cancer, offering new visibility into what traditional imaging cannot detect. 1 MRD tests, like the Oncodetect® test ...
Experts discuss how MRD testing in myeloma increasingly guides frontline care, yet unanswered questions still limit using MRD as the sole benchmark. This episode, titled 'MRD Negativity as a Benchmark ...
Zacks Investment Research on MSN
Biodesix expands MRD testing with tumor-informed and tumor-naive tests
Biodesix BDSX recently announced strategic progress in two molecular residual disease (MRD) programs to expand access to ...
Experts debate quadruplet myeloma therapy, MRD-guided de-escalation, and risk-adapted intensification—plus how payers may respond. This episode, titled 'From Trial Data to Clinical Practice: DVRd, MRD ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Tumor-informed ctDNA testing with the Signatera assay outperformed standard PET/CT imaging across B- and T-cell lymphoma subtypes. Data from a prospective, real-world cohort demonstrated that ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CURE spoke with a provider and a survivor about the potential power of minimal residual disease testing. Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to ...
NCCN consolidates MRD guidance on a new MYEL-E page, standardizing bone marrow–based MRD assessment using NGS or multicolor flow cytometry across the treatment continuum. Preferred analytical ...
Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), By Cancer Type (Hematological Malignancy, Solid ...
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 ...
Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results